BiotechTube

Sonelokimab + Placebo + Adalimumab

Phase 2Completed
1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Arthritis, Psoriatic

Conditions

Arthritis, Psoriatic

Trial Timeline

Dec 13, 2022 → Jan 15, 2024

NCT ID
NCT05640245

About Sonelokimab + Placebo + Adalimumab

Sonelokimab + Placebo + Adalimumab is a phase 2 stage product being developed by MoonLake Immunotherapeutics for Arthritis, Psoriatic. The current trial status is completed. This product is registered under clinical trial identifier NCT05640245. Target conditions include Arthritis, Psoriatic.

What happened to similar drugs?

20 of 20 similar drugs in Arthritis, Psoriatic were approved

Approved (20) Terminated (0) Active (0)
✅NISEDr. Reddy's LaboratoriesApproved
✅Duloxetine + Sugar pillEli LillyApproved
✅Baricitinib + TNF InhibitorEli LillyApproved
✅Ixekizumab + AdalimumabEli LillyApproved
✅TacrolimusAstellas PharmaApproved
✅tacrolimus + methotrexate + adalimumab + tocilizumab + abataceptAstellas PharmaApproved
✅tacrolimus + placeboAstellas PharmaApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05640245Phase 2Completed

Competing Products

20 competing products in Arthritis, Psoriatic

See all competitors
ProductCompanyStageHype Score
DRL_RI + Rituxan + MabTheraDr. Reddy's LaboratoriesPhase 1/2
29
Experimental: Arm A: DRL_RI + Arm B: Rituxan®/Mabthera®Dr. Reddy's LaboratoriesPhase 3
37
NISEDr. Reddy's LaboratoriesApproved
40
NISELATDr. Reddy's LaboratoriesPre-clinical
23
Test Product + Reference product + Reference Medicinal ProductDr. Reddy's LaboratoriesPhase 1
22
Tocilizumab Prefilled SyringeDr. Reddy's LaboratoriesPhase 1
26
TilmanoceptNavidea BiopharmaceuticalsPhase 1
11
Tc99m tilmanoceptNavidea BiopharmaceuticalsPhase 2
25
KPL-404 + PlaceboKiniksa PharmaceuticalsPhase 2
29
Baricitinib + Methotrexate + Baricitinib Placebo + MTX Placebo + Folic AcidEli LillyPhase 3
40
Duloxetine + PlaceboEli LillyPhase 3
40
LY2828360 + PlaceboEli LillyPhase 2
35
Investigational Medical Product (IMP) administered in parent studyEli LillyPhase 3
40
SonelokimabMoonLake ImmunotherapeuticsPhase 3
41
Sonelokimab + PlaceboMoonLake ImmunotherapeuticsPhase 3
38
Sonelokimab + Placebo + RisankizumabMoonLake ImmunotherapeuticsPhase 3
41
Dose A VTX958 + Dose B VTX958 + PlaceboVentyx BiosciencesPhase 2
21
LY2127399Eli LillyPhase 3
32
Ixekizumab + PlaceboEli LillyPhase 3
40
Duloxetine + Sugar pillEli LillyApproved
43